SecBot SecBot
8-K ·Filed Aug 14, 2026

LFWD

Lifeward Ltd.
MIXED
Impact 6/10
Horizonweeks Processed3mo ago SEC0001178913-26-004140
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The 16% revenue growth is a clear positive signal that the commercial strategy is gaining traction, but the CFO departure and board exits introduce execution risk. Monitor the search for a new CFO and whether the company can sustain revenue momentum into H2 2026. The $5.6M in additional contingent capital tied to a 150% ReWalk sales increase or a $13.80 stock price is a potential catalyst but also a high bar.

DirectionMixed
Confidencemedium
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Lifeward reported Q2 2026 revenue of $6.6M (+16% YoY), its strongest quarter since Q4 2024, driven by growth in ReWalk and AlterG sales. However, the GAAP net loss widened to -$11.5M due to non-cash warrant revaluation charges, and the company announced the departure of its CFO and three board members, creating governance uncertainty. The combination of improving top-line momentum and significant management turnover presents a mixed picture for the stock.

Key Financial Metrics

EPS
−$4.12
Revenue
$6.6M
+15.7% YoY
Rating
in line
Gross Margin
40.9%

Key Facts

  • Revenue increased 16% YoY to $6.6M, the strongest quarterly revenue since Q4 2024.
  • GAAP net loss was -$11.5M, or -$4.12 per share, compared to -$6.6M in Q2 2025, driven by $6.9M in non-cash fair value remeasurement of warrant and derivative liabilities.
  • Non-GAAP adjusted net loss was -$4.1M, compared to -$3.5M in Q2 2025, with the increase primarily due to $0.7M in Oratech clinical trial costs.
  • Cash balance was $9.4M as of June 30, 2026, with a proforma balance of ~$11M after a July 2026 capital raise.
  • CFO Almog Adar will depart effective September 30, 2026; Chairman Bob Marshall and Directors Mike Swinford and William Sigsbee stepped down from the board.
  • Gross margin declined to 41% from 44% YoY due to tariffs, FX, and a 4% revenue sharing expense from the Oramed transaction.

Financial Impact

Revenue growth of $0.9M (+16% YoY) offset by a $4.9M increase in GAAP net loss due to non-cash warrant charges. Operating cash burn for H1 2026 was -$9.7M, roughly in line with H1 2025.

revenuenet losscashoperating expenses

Risk Factors

  • CFO departure and board turnover create leadership vacuum and potential strategic drift.
  • GAAP net loss widening due to non-cash warrant charges; operating cash burn remains elevated at -$9.7M in H1 2026.
  • Gross margin compression from tariffs, FX, and Oramed revenue sharing could pressure profitability.
  • Dependence on contingent capital raise tied to aggressive sales or stock price targets.

Market Snapshot

Exchange
Nasdaq
Sector
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001178913-26-004140
Document: zk2635970.htm0001178913-26-004140
Document: 0001178913-26-004140-index-headers.html0001178913-26-004140
Document: 0001178913-26-004140-index.html0001178913-26-004140
Document: 0001178913-26-004140.txt0001178913-26-004140
8-K Data (Synthetic)0001178913-26-004140

Track record

25 reports on LFWD

Performance horizon

7 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +20.27% at T+60 after the Aug 14, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Bearish 6/10 Entry $4.06 Now $3.62 +10.84% settles Nov 20
  2. Nov 12, 20264d ago 3 Neutral 1/10 Entry $4.06 Now $3.62 −10.84% settles Nov 20
  3. Nov 3, 202613d ago 3 Neutral 2/10 Entry $6.06 to $5.76 Now $3.62 −40.26% ▼ −4.95% −4.04% vs SPY
  4. Oct 27, 202620d ago 8-K Neutral 2/10 Entry $6.04 to $5.83 Now $3.62 −40.07% ▼ −3.48% −1.49% vs SPY
  5. Oct 8, 20265w ago 8-K Bearish 5/10 Entry $6.49 to $6.00 Now $3.62 +44.22% ▲ +7.55% +5.58% vs SPY
  6. Oct 1, 20266w ago 8-K Neutral 2/10 Entry $5.96 to $6.43 Now $3.62 −39.26% ▲ +7.89% +6.58% vs SPY
  7. Sep 25, 20267w ago DEF 14A Bearish 7/10 Entry $6.92 to $6.67 Now $3.62 +47.69% ▲ +3.61% +4.82% vs SPY
  8. Aug 14, 202613w ago 8-K Mixed 6/10 Viewing No price data
  9. Aug 14, 202613w ago Press Release Bearish 6/10 Entry $7.45 to $7.32 Now $3.62 +51.41% ▲ +1.75% +0.38% vs SPY
  10. Aug 11, 202614w ago EFFECT Bearish 7/10 Entry $7.57 to $7.41 Now $3.62 +52.15% ▲ +2.08% +1.67% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 9h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 14, 2026